JP2021098732A5 - - Google Patents

Download PDF

Info

Publication number
JP2021098732A5
JP2021098732A5 JP2021037440A JP2021037440A JP2021098732A5 JP 2021098732 A5 JP2021098732 A5 JP 2021098732A5 JP 2021037440 A JP2021037440 A JP 2021037440A JP 2021037440 A JP2021037440 A JP 2021037440A JP 2021098732 A5 JP2021098732 A5 JP 2021098732A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021037440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021098732A (ja
Filing date
Publication date
Priority claimed from JP2020508477A external-priority patent/JP2020531438A/ja
Application filed filed Critical
Publication of JP2021098732A publication Critical patent/JP2021098732A/ja
Publication of JP2021098732A5 publication Critical patent/JP2021098732A5/ja
Pending legal-status Critical Current

Links

JP2021037440A 2017-08-16 2021-03-09 Nkg2d、cd16、およびegfr、ccr4、またはpd−l1に結合するタンパク質 Pending JP2021098732A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762546300P 2017-08-16 2017-08-16
US201762546297P 2017-08-16 2017-08-16
US62/546,300 2017-08-16
US62/546,297 2017-08-16
US201762552152P 2017-08-30 2017-08-30
US62/552,152 2017-08-30
US201762555114P 2017-09-07 2017-09-07
US62/555,114 2017-09-07
JP2020508477A JP2020531438A (ja) 2017-08-16 2018-08-16 Nkg2d、cd16、およびegfr、hla−e、ccr4、またはpd−l1に結合するタンパク質

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020508477A Division JP2020531438A (ja) 2017-08-16 2018-08-16 Nkg2d、cd16、およびegfr、hla−e、ccr4、またはpd−l1に結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2021098732A JP2021098732A (ja) 2021-07-01
JP2021098732A5 true JP2021098732A5 (cg-RX-API-DMAC7.html) 2021-09-24

Family

ID=65362495

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020508477A Pending JP2020531438A (ja) 2017-08-16 2018-08-16 Nkg2d、cd16、およびegfr、hla−e、ccr4、またはpd−l1に結合するタンパク質
JP2021037440A Pending JP2021098732A (ja) 2017-08-16 2021-03-09 Nkg2d、cd16、およびegfr、ccr4、またはpd−l1に結合するタンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020508477A Pending JP2020531438A (ja) 2017-08-16 2018-08-16 Nkg2d、cd16、およびegfr、hla−e、ccr4、またはpd−l1に結合するタンパク質

Country Status (12)

Country Link
US (2) US20200216544A1 (cg-RX-API-DMAC7.html)
EP (2) EP3882270A3 (cg-RX-API-DMAC7.html)
JP (2) JP2020531438A (cg-RX-API-DMAC7.html)
KR (2) KR20210029298A (cg-RX-API-DMAC7.html)
CN (2) CN113004391A (cg-RX-API-DMAC7.html)
AU (2) AU2018318698A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020003050A2 (cg-RX-API-DMAC7.html)
CA (3) CA3073117A1 (cg-RX-API-DMAC7.html)
IL (2) IL272553A (cg-RX-API-DMAC7.html)
MX (2) MX2020001805A (cg-RX-API-DMAC7.html)
SG (2) SG10202102251YA (cg-RX-API-DMAC7.html)
WO (1) WO2019035939A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
SG11202011139YA (en) * 2018-05-16 2020-12-30 Dragonfly Therapeutics Inc Protein binding nkg2d, cd16 and a fibroblast activation protein
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
CN115708411A (zh) * 2020-04-16 2023-02-21 南通壹宸生物医药科技有限公司 一种pd-1突变体多肽及其制备和用途
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
BR112023002116A2 (pt) * 2020-08-05 2023-04-25 Dragonfly Therapeutics Inc Proteínas que se ligam a nkg2d, cd16 e egfr
CN116063550A (zh) * 2020-09-02 2023-05-05 南京北恒生物科技有限公司 靶向nk激活性受体的嵌合抗原受体
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
CN115246886A (zh) * 2021-04-27 2022-10-28 丹生医药技术(上海)有限公司 一种抗egfr/vegf双功能融合蛋白及其用途
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF
CN116284430A (zh) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 靶向肿瘤的il15融合蛋白及其应用
WO2023043861A2 (en) * 2021-09-16 2023-03-23 Biohaven Therapeutics Ltd. Conjugated antibodies for treating diseases
CN118201961A (zh) * 2021-09-16 2024-06-14 Gt生物制药公司 Pd-l1靶向融合蛋白及其使用方法
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
EP4476263A4 (en) * 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16
JP2025528087A (ja) * 2022-08-05 2025-08-26 チマゲン・バイオサイエンシズ,リミテッド 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体
CN121100134A (zh) * 2023-04-14 2025-12-09 山东先声生物制药有限公司 一种靶向人cd16和肿瘤抗原的多特异性抗体
CN121443647A (zh) * 2023-07-07 2026-01-30 四川科伦博泰生物医药股份有限公司 EGFR/c-MET双特异性结合蛋白及其用途
KR20260051102A (ko) * 2023-07-07 2026-04-15 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Egfr/c-met 이중특이적 결합 단백질 및 이의 용도
CN121568966A (zh) * 2023-07-19 2026-02-24 映恩生物制药(苏州)有限公司 一种双特异性抗体、其药物偶联物及其用途
CN121868507A (zh) * 2024-10-16 2026-04-17 上海安领科生物医药有限公司 抗EGFR和cMET双特异性抗体的抗体药物偶联物
WO2026098440A1 (zh) * 2024-11-05 2026-05-15 上海齐鲁制药研究中心有限公司 一种双特异性抗体偶联物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1945771A1 (en) * 2005-10-28 2008-07-23 Novo Nordisk A/S Fusion proteins that bind effector lymphocytes and target cells
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
MX2009012343A (es) * 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9562110B2 (en) * 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
RU2017105425A (ru) * 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
CN107074961A (zh) * 2014-11-03 2017-08-18 默克专利股份公司 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
CA2972800A1 (en) * 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
WO2016122701A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
US20180147257A1 (en) * 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
AU2017222700B2 (en) * 2016-02-26 2018-09-27 Imunexus Therapeutics Limited Multi-specific molecules

Similar Documents

Publication Publication Date Title
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2021098733A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2022551969A5 (cg-RX-API-DMAC7.html)
JP2021512630A5 (cg-RX-API-DMAC7.html)
JP2023106433A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2021533169A5 (cg-RX-API-DMAC7.html)
JP2020522473A5 (cg-RX-API-DMAC7.html)
JP2023052214A5 (cg-RX-API-DMAC7.html)
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP2021035388A5 (ja) Caix、ano1、メソテリン、trop2またはクローディン−18.2を標的にする多重特異性結合タンパク質
Godar et al. Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
JP2020536543A5 (cg-RX-API-DMAC7.html)
JP2020521448A5 (cg-RX-API-DMAC7.html)
JP2020529410A5 (cg-RX-API-DMAC7.html)
JP2021521275A5 (cg-RX-API-DMAC7.html)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2021522162A5 (cg-RX-API-DMAC7.html)
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
JP2018537966A5 (cg-RX-API-DMAC7.html)
JP2020508997A5 (cg-RX-API-DMAC7.html)
JP2020507328A5 (cg-RX-API-DMAC7.html)
JP2020522474A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)